Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2026-03-04 @ 10:29 AM
Study NCT ID:
NCT04687969
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-25
First Post:
2020-12-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multimodal Machine Learning Characterization of Solid Tumors
Sponsor:
Ciprian Catana, MD, PhD
Organization:
Study Overview
Official Title:
Multimodal PET/MRI Machine Learning Approaches for Characterization of Solid Tumors
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study wants to develop advanced imaging methods to more accurately characterize prostate cancer or solid tumor aggressiveness.
This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
This observational study involves \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI)
Detailed Description:
This is an observational imaging study to evaluate the value of multimodal \[18F\]DCFPyL positron emission tomography and magnetic resonance imaging (PET/MRI) for solid tumor characterization and disease staging.
This research study involves:
* Screening visit, and 1-3 study Multimodal \[18F\]DCFPyL PET/MRI visits
* Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma)
* It is expected that about 135 people will take part in this research study
* The PET dye used in this study is called \[18F\]DCFPyL. \[18F\]DCFPyL is approved by the U.S. Food and Drug administration (FDA).
* The PET/MRI scanner was approved by the U.S. FDA.
This research study involves:
* Screening visit, and 1-3 study Multimodal \[18F\]DCFPyL PET/MRI visits
* Two cohorts of participants will be enrolled in this study: primary prostate cancer patients and patients with known or suspected solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma)
* It is expected that about 135 people will take part in this research study
* The PET dye used in this study is called \[18F\]DCFPyL. \[18F\]DCFPyL is approved by the U.S. Food and Drug administration (FDA).
* The PET/MRI scanner was approved by the U.S. FDA.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01CA218187 | NIH | None | https://reporter.nih.gov/quic… | View |